Background
Phase 1/2 single-arm study (HGB-206; NCT02140554). N=35 with SCD (HbSS or HbSβ0), Group C (≥18 yr, ≥4 severe VOC in prior 24 mo). Lovo-cel (lovotibeglogene autotemcel; bb1111): BB305 lentiviral vector encoding modified βA-T87Q antisickling globin inserted into autologous HSPCs. FDA approved Dec 8, 2023 (Lyfgenia); bluebird bio commercially discontinued US April 2024.
Interventions and follow up
Treatment: Single IV infusion of lovo-cel (bb1111) after busulfan myeloablative conditioning, refined Group C manufacturing protocol
Primary endpoint: Proportion achieving HbA-T87Q ≥30% and complete resolution of severe VOC from 6 mo post-infusion
Median follow-up: 17.3 mo (range 3.7–37.6)
Primary endpoint: Proportion achieving HbA-T87Q ≥30% and complete resolution of severe VOC from 6 mo post-infusion
Median follow-up: 17.3 mo (range 3.7–37.6)
Results
VOC resolution: 25/25 evaluable (100%) complete resolution of severe VOC (vs median 3.5 events/yr pre-treatment)
Total Hgb: Median ≥11 g/dL from 6 to 36 mo post-infusion
HbA-T87Q: ≥40% of total Hgb in mean 85±8% of red cells
Hemolysis markers: Substantially reduced (indirect bilirubin, LDH)
Total Hgb: Median ≥11 g/dL from 6 to 36 mo post-infusion
HbA-T87Q: ≥40% of total Hgb in mean 85±8% of red cells
Hemolysis markers: Substantially reduced (indirect bilirubin, LDH)
Adverse events
Conditioning/HSCT-related: Febrile neutropenia, mucositis, engraftment syndrome, veno-occlusive disease
Malignancy: 1 patient from earlier Group A (different protocol) developed AML ~5.5 yr post-infusion; deemed unlikely vector-related (insertion site analysis, no surrounding gene dysregulation)
Drug-related AEs: 3 non-serious AEs related to lovo-cel (resolved <1 wk)
Deaths: No treatment-related deaths in Group C
Malignancy: 1 patient from earlier Group A (different protocol) developed AML ~5.5 yr post-infusion; deemed unlikely vector-related (insertion site analysis, no surrounding gene dysregulation)
Drug-related AEs: 3 non-serious AEs related to lovo-cel (resolved <1 wk)
Deaths: No treatment-related deaths in Group C
Conclusions
Lovo-cel produced sustained HbA-T87Q and complete resolution of severe VOC in all 25 evaluable SCD patients, providing proof-of-concept for lentiviral gene-addition therapy as a curative approach in SCD.
Key Limitations
Small single-arm cohort (n=35), no comparator. Surrogate-heavy endpoints (Hgb, HbA-T87Q). Requires myeloablative conditioning with attendant toxicity/infertility. Limited follow-up; AML signal in earlier-protocol patient raises insertional-mutagenesis surveillance concerns. Generalizability limited by stringent eligibility.
Clinical Context
Supported FDA approval of Lyfgenia (Dec 2023) for severe SCD ≥12 yr; black-box warning for hematologic malignancy. One of two SCD gene therapies (alongside CRISPR-based exa-cel); ASH considers gene therapy for transfusion/hydroxyurea-refractory severe SCD lacking matched donor. Commercially discontinued in US April 2024.